Cabaletta Bio Q1 2024 Earnings Report
Key Takeaways
Cabaletta Bio reported first quarter 2024 financial results, highlighting the progress of CABA-201 clinical trials and advancements in optimizing patient experience, along with upcoming presentations of initial clinical data.
No CRS or ICANS of any grade were observed in either of the first patients dosed with CABA-201 in the RESET-Myositis and RESET-SLE trials.
Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials will be presented at a satellite symposium at the EULAR 2024 Congress in June.
Cabaletta is evaluating CABA-201 without preconditioning by initiation of the RESET-PV sub-study within the ongoing DesCAARTes trial in pemphigus vulgaris.
The company demonstrated the potential to eliminate the need for apheresis by using a blood draw to obtain the starting material for the CABA-201 manufacturing process.
Cabaletta Bio
Cabaletta Bio
Forward Guidance
Cabaletta Bio expects that its cash, cash equivalents and short-term investments as of March 31, 2024, will enable it to fund its operating plan into the first half of 2026.